Evaluation of heterophilic antibody blocking agents in reducing false positive interference in immunoassays for IL-17AA, IL-17FF, and IL-17AF.
IL-17AA, IL-17FF, and IL-17AF are proinflammatory cytokines that have been implicated in the pathogenesis of autoimmune diseases such as rheumatoid arthritis (RA). In order to measure the levels of these cytokines in synovial fluid and serum samples from RA patients, immunoassays specific for IL-17AA, FF, and AF were developed. Although these assays could tolerate up to 50% pooled normal human serum, false positive reactivity was problematic in patient samples suggesting interference from heterophilic antibodies. We therefore evaluated the ability of several commercially available heterophilic antibody blocking agents to reduce false positive reactivity by testing them against samples that were confirmed as false positives in the IL-17AA, FF, and AF assays. Several of the blockers performed well, including HBR-1, HBR-9, HBR-11, HBR-Plus, Serum Cytokine Assay Diluent, and IIR. We chose to move forward using IIR blocker for sample analysis and verified that IIR had no effect on the assay standard curves and did not affect IL-17 quantitation in plasma from ex vivo stimulated human whole blood. IL-17FF and IL-17AF were below the limits of quantitation of the assays (12.3 and 10.5pg/ml, respectively) in synovial fluid and serum samples from patients with RA and osteoarthritis (OA). For the more sensitive IL-17AA assay (1.6pg/ml limit of quantitation), low levels of IL-17AA were measurable in 48% of RA synovial fluid samples (mean, 7.9pg/ml; median, <1.6pg/ml; range, <1.6-29.7pg/ml; n=23) but not in synovial fluid from patients with OA (n=33). For serum samples, however, IL-17AA was below the limit of detection for both RA and OA patients. When these same serum samples were analyzed in the absence of a heterophilic antibody blocker, false positive reactivity yielded apparent mean IL-17AA levels of 43.3pg/ml (28% positive; n=50) and 14.8pg/ml (12% positive; n=50) for RA and OA patients, respectively, results that could potentially be interpreted as consistent with disease biology. These studies demonstrate the importance of ensuring that HAb interference is well controlled, particularly when measuring low concentrations of cytokines in samples from patients with autoimmune disease.
DeForge
Laura E
LE
Department of Assay & Automation Technology, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA. deforge@gene.com
Loyet
Kelly M
KM
Delarosa
Donnie
D
Chinn
Jason
J
Zamanian
Fojan
F
Chuntharapai
Anan
A
Lee
James
J
Hass
Phil
P
Wei
Nathan
N
Townsend
Michael J
MJ
Wang
Jianyong
J
Wong
Wai Lee T
WL
D000368:Aged; D000369:Aged, 80 and over; D000906:Antibodies / Q000737:chemistry / Q000276:immunology; D001172:Arthritis, Rheumatoid / Q000097:blood* / Q000276:immunology; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods / Q000592:standards; D005189:False Positive Reactions; D005260:Female; D006801:Humans; D020381:Interleukin-17 / Q000097:blood* / Q000276:immunology; D008297:Male; D008875:Middle Aged; D010003:Osteoarthritis / Q000097:blood* / Q000276:immunology; D012680:Sensitivity and Specificity; D013582:Synovial Fluid / Q000276:immunology / Q000378:metabolism*
D000906:Antibodies; C508717:IL17A protein, human; C440021:IL17F protein, human; D020381:Interleukin-17